Australian access to FDA-approved breakthrough therapy designation medicines: a 10-year review
- Author(s)
- Lingaratnam, S; Hussainy, SY; Murphy, A; Perrin, C; Samuvel, M; Mehrvarz, E; Lim, CX; Zalcberg, J;
- Details
- Publication Year 2024,Volume 17,Issue #1,Page 2389120
- Journal Title
- Journal of Pharmaceutical Policy and Practice
- Publication Type
- Review
- Abstract
- BACKGROUND: Regulatory pathways adopted by the United States Food Drug and Administration (FDA) and Australian Therapeutic Goods Administration (TGA) enable expedited approval of medicines that are thought to offer significant clinical advantage over existing options for severe diseases. OBJECTIVES: To review Australian accessibility to medicines approved through the FDA breakthrough therapy designation (BTD) process including timelines and approvals by the TGA and Pharmaceutical Benefits Advisory Committee (PBAC) for listing on the Pharmaceutical Benefits Scheme (PBS). METHODS: Retrospective review of published reports from the FDA, TGA, PBAC and PBS for BTDs from 1 January 2013-31 August 2023. Uniform data about BTD and milestone dates were collected. Analysis included all BTDs approved by FDA until 31-August-2022. Main outcome measures: Rates of approval by TGA and PBAC, and PBS-listing; and median (interquartile range, IQR) time from FDA submission to FDA approval, and FDA approval to TGA approval, PBAC approval and PBS listing for cancer and non-cancer medicines. RESULTS: Of 237 BTDs across 156 medicines, 68% were approved by the TGA, and 37% were listed on the PBS. Median (IQR) time from FDA submission to FDA approval was shorter for cancer compared to non-cancer; 179 days (140-210) vs 232 days (181-245), p < 0.02. Time from FDA approval to PBS listing was similar for cancer and non-cancer; median 744 days (IQR, 549-1136) and 733 days (IQR 440-960) respectively, with improvements for cancer BTDs noted for 2018-2022 compared to 2013-2017; 566 days (IQR 319-831) vs 880 days (IQR 620-1362), p < 0.02 but not for non-cancer BTDs. CONCLUSION: BTD medicines are accessible in Australia approximately 2 years after FDA approval. Since 2018, time to PBS listing for cancer therapies improved, mirroring shorter FDA approval times for this category. Further understanding of clinical studies and context by therapeutic area may improve timely and safe access to life-saving medicines.
- Publisher
- Taylor & Francis
- Keywords
- Drug approval; access; government regulation; humans
- Department(s)
- Pharmacy
- Publisher's Version
- https://doi.org/10.1080/20523211.2024.2389120
- Open Access at Publisher's Site
https://doi.org/10.1080/20523211.2024.2389120- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-09-19 02:48:13
Last Modified: 2024-09-19 02:49:37